In Brief: Wyeth-Ayerst's Lodine (etodolac)
Executive Summary
Wyeth-Ayerst's Lodine (etodolac): FDA's Arthritis Advisory Committee will not discuss use of the NSAID in rheumatoid arthritis, as originally scheduled, at the committee's March 27 meeting. Open committee discussion portion of the meeting has been cancelled. There will be an open public hearing from 9-10 a.m. at the Holiday Inn, Silver Spring, Md...